For some years now, independent analysts see Werum as the worldwide leading supplier of MES for pharmaceutical companies. At the same time, Werum is in this business segment one of the few globally operating MES software providers that are separate legal entities and truly inde-pendent. Our PAS-X product can be integrated with all ERP and DCS/SCADA systems available on the market, so that it can be used it in a really vendor-neutral manner.
Since the introduction of the first comprehensive product version to the market in 1994, PAS-X has developed into the leading MES product in this market segment.
Today, PAS-X is used in over 500 installations in more than 30 countries worldwide. Most of these installations have been validated by the FDA or by the national authorities.
Our customers include 16 of the world's 30 largest pharmaceutical companies. We have also joined forces and formed strategic MES partnerships with well known industry leaders, which include among others Amgen, Astellas, AstraZeneca, Bayer HealthCare, B. Braun, Boehringer Ingelheim, Genzyme, Merck & Co., Merck Serono, Novartis, Novo Nordisk and Sandoz. With some of our customers we have, in addition, concluded global framework agreements for the de-livery of MES systems.
We are committed to create a stable and sustainable long-term partnership with our customers. On a global basis, we can ensure high-standard services and technically excellent support and as-sistance, and - on request - we can assume the full responsibility for the introduction of a system.
Market research organizations, such as ARC, Gartner (AMR), Aberdeen and Frost & Sullivan, predict that investments in MIT in the pharmaceutical industry will still continue to increase sub-stantially over the next several years.
A number of developments are driving this growth:
Lower profit margins and the resulting concentration of the pharmaceutical market require additional focus on streamlining manufacturing processes:
Large pharmaceutical companies are looking to harmonize their MES environments
Medium-sized pharmaceutical companies are focusing on implementing highly stan-dardized MES products
Use of methods to optimize lead times and to reduce error rates, such as:
Right-first-Time Approach
Lean Manufacturing
Quality by Design (QbD)
Release by Exception
We expect to benefit from this market development and to increase our business volume and market share even further over the coming years.
![\"\"](\"/images/1px.gif\"){kind=spacer}
Leading MES Product
PAS-X: Milestones of Development;)
Top of Page